Evidence map›Paper›PMID 41226530›Full record

ArticleInternational journal of molecular sciences2025

Cable Cars to the Nucleus: TM4SF1-Enriched Microdomains Conduct Signaling in Endothelial Cells for Blood Vessel Formation.

Shou-Ching Jaminet

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shou-Ching JaminetAngiex Inc., 150 Cambridge Park Drive, Cambridge, MA 02140, USA.ORCID 0009-0003-6358-7574

Funding

Angiex Angiex
6 · The paper itself

Abstract

Endothelial cell proliferation, migration, and intercellular interactions for blood vessel formation require coordinated signaling by a myriad of molecules. Following endothelial cell activation by growth factors and cytokines, a variety of signaling molecules are activated on the surface and transported intracellularly by TM4SF1-enriched microdomains (TMEDs), 100-300 nm diameter protein-lipid complexes recruited by the transmembrane protein TM4SF1. TMEDs internalize via microtubules from the cell surface toward the microtubule-organizing center (MTOC) and then enter the nucleus via nuclear pores (see Graphic Illustration). This internalization pathway permits delivery of activated proteins and other signaling molecules from the cell surface to the nucleus, which directly translates extracellular stimuli to modulation of gene expression. Molecules transported by this route include phospholipase C, gamma 1 (PLCγ1), histone deacetylase 6 (HDAC6), and importins. In the absence of TMEDs, endothelial cells lose the ability to divide into cultures in vitro and to support blood vessel formation in mouse embryos in vivo. We liken TMEDs to cable cars, which take in passengers at the cell surface, travel along microtubule cables, and deliver their passengers to various locations, including the "city center", the nucleus. This commentary aims to elucidate the functions of TMEDs in endothelial cells, to show that cells, like busy cities, need efficient transport systems to deliver molecules to the destinations where they perform their cellular functions. TMEDs offer a novel and curated transport system providing selected molecules with access to the nucleus.

Indexed as

Blood VesselsCell NucleusEndothelial CellsMembrane MicrodomainsMembrane ProteinsNeovascularization, PhysiologicSignal TransductionAnimalsHumansMiceMicrotubulesMembrane Proteinsangiogenesisblood vessel developmentendothelial cell signalingnanopodiatetraspaninTM4SF1TMEDSVEGF-A

Identifiers

PMID41226530
PMCPMC12611028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.